

New Redeye Interview with CEO Hanna Sjöström

In a new interview with Redeye analyst Gustaf Meyer, CEO Hanna Sjöström discusses the reported positive safety results from Neola Medical's first clinical pilot study, key insights and the next phase of clinical development.

Watch the full interview here: [Redeye Interview Neola Medical Reports Positive Safety Results from First Clinical Pilot Study with CEO Hanna Sjöström](#)

Access additional insights from Redeye here: <https://www.redeye.se/company/neola-medical>

For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical

Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung collapse in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on near-infrared light measurements in the lungs. Neola Medical builds on Sweden's longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Image Attachments

[Photo New Redeye Interview with CEO Hanna Sjöström](#)

Attachments

[New Redeye Interview with CEO Hanna Sjöström](#)